BACKGROUND: HIV infection and its treatment are associated with abnormal lipid profiles. High triglyceride concentrations and low HDL-cholesterol concentrations are the most common health abnormalities and raise concerns about an increased risk of cardiovascular disease. OBJECTIVE: We compared the fatty acid patterns of serum phospholipids between persons with HIV and non-HIV controls to determine whether there are differences that explain the elevated triglyceride concentrations, insulin resistance, and inflammation that are part of the metabolic syndrome in patients with HIV. DESIGN: Thirty-nine persons with HIV and elevated serum triglycerides (>150 mg/dL) and/or indicators of insulin resistance were recruited to examine fatty acid profiles in serum phospholipid fractions relative to those of 2 control groups without HIV (n = 31). RESULTS: Higher concentrations of 16:1 and 18:0 fatty acids in the phospholipid fraction indicated increased lipogenesis in the HIV patients and in the non-HIV controls at risk of the metabolic syndrome. However, the subjects with HIV had higher concentrations of both n-6 (omega-6) and n-3 fatty acids of higher elongation and desaturation levels, which indicated a greater promotion of these pathways in this population. The nanomolar percentage (%nmol) arachidonic acid was the same in all 3 groups. CONCLUSIONS: Persons with and without HIV, at risk of the metabolic syndrome, show indications of increased lipogenesis, more so in subjects with HIV taking medication. Higher proportions of distal elongation and desaturation fatty acid products were seen only in the phospholipids fatty acid fraction of the subjects with HIV.
BACKGROUND:HIV infection and its treatment are associated with abnormal lipid profiles. High triglyceride concentrations and low HDL-cholesterol concentrations are the most common health abnormalities and raise concerns about an increased risk of cardiovascular disease. OBJECTIVE: We compared the fatty acid patterns of serum phospholipids between persons with HIV and non-HIV controls to determine whether there are differences that explain the elevated triglyceride concentrations, insulin resistance, and inflammation that are part of the metabolic syndrome in patients with HIV. DESIGN: Thirty-nine persons with HIV and elevated serum triglycerides (>150 mg/dL) and/or indicators of insulin resistance were recruited to examine fatty acid profiles in serum phospholipid fractions relative to those of 2 control groups without HIV (n = 31). RESULTS: Higher concentrations of 16:1 and 18:0 fatty acids in the phospholipid fraction indicated increased lipogenesis in the HIV patients and in the non-HIV controls at risk of the metabolic syndrome. However, the subjects with HIV had higher concentrations of both n-6 (omega-6) and n-3 fatty acids of higher elongation and desaturation levels, which indicated a greater promotion of these pathways in this population. The nanomolar percentage (%nmol) arachidonic acid was the same in all 3 groups. CONCLUSIONS:Persons with and without HIV, at risk of the metabolic syndrome, show indications of increased lipogenesis, more so in subjects with HIV taking medication. Higher proportions of distal elongation and desaturation fatty acid products were seen only in the phospholipids fatty acid fraction of the subjects with HIV.
Authors: K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2000-01-01 Impact factor: 3.731
Authors: F Pérez-Jiménez; J López-Miranda; M D Pinillos; P Gómez; E Paz-Rojas; P Montilla; C Marín; M J Velasco; A Blanco-Molina; J A Jiménez Perepérez; J M Ordovás Journal: Diabetologia Date: 2001-11 Impact factor: 10.122
Authors: L K M Summers; B A Fielding; H A Bradshaw; V Ilic; C Beysen; M L Clark; N R Moore; K N Frayn Journal: Diabetologia Date: 2002-03 Impact factor: 10.122
Authors: A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: B Vessby; M Uusitupa; K Hermansen; G Riccardi; A A Rivellese; L C Tapsell; C Nälsén; L Berglund; A Louheranta; B M Rasmussen; G D Calvert; A Maffetone; E Pedersen; I B Gustafsson; L H Storlien Journal: Diabetologia Date: 2001-03 Impact factor: 10.122
Authors: J C Lovejoy; C M Champagne; S R Smith; J P DeLany; G A Bray; M Lefevre; Y M Denkins; J C Rood Journal: Metabolism Date: 2001-01 Impact factor: 8.694
Authors: D E Laaksonen; T A Lakka; H-M Lakka; K Nyyssönen; T Rissanen; L K Niskanen; J T Salonen Journal: Diabet Med Date: 2002-06 Impact factor: 4.359
Authors: Margo N Woods; Christine A Wanke; Pei-Ra Ling; Kristy M Hendricks; Alice M Tang; Tamsin A Knox; Charlotte E Andersson; Kimberly R Dong; Sally C Skinner; Bruce R Bistrian Journal: Am J Clin Nutr Date: 2009-10-21 Impact factor: 7.045
Authors: Salma A Abdelmagid; Shannon E Clarke; Daiva E Nielsen; Alaa Badawi; Ahmed El-Sohemy; David M Mutch; David W L Ma Journal: PLoS One Date: 2015-02-12 Impact factor: 3.240
Authors: Pragney Deme; Leah H Rubin; Danyang Yu; Yanxun Xu; Gertrude Nakigozi; Noeline Nakasujja; Aggrey Anok; Alice Kisakye; Thomas C Quinn; Steven J Reynolds; Richard Mayanja; James Batte; Maria J Wawer; Ned C Sacktor; Deanna Saylor; Norman J Haughey Journal: Viruses Date: 2022-06-15 Impact factor: 5.818